{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:10:53Z","timestamp":1788174653860,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015519","name":"University of Caen Normandy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015519","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.leukres.2025.107716","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T23:30:48Z","timestamp":1747265448000},"page":"107716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-907X","authenticated-orcid":false,"given":"Hyacinthe","family":"Johnson-Ansah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Roth-Gu\u00e9pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Cayssials","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-1559","authenticated-orcid":false,"given":"Delphine","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Flandrin-Gresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Dulucq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Hayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck-Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5379-7461","authenticated-orcid":false,"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10314","key":"10.1016\/j.leukres.2025.107716_bib1","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.leukres.2025.107716_bib2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2025.107716_bib3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"International BCR-ABL Study Group. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2025.107716_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0950-3536(97)80003-0","article-title":"BCR-ABL gene variants","volume":"10","author":"Melo","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107716_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ajh.10456","article-title":"Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory","volume":"75","author":"Snyder","year":"2004","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2025.107716_bib6","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1007\/s00432-021-03569-8","article-title":"Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network","volume":"147","author":"Sch\u00e4fer","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107716_bib7","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107716_bib8","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2025.107716_bib9","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.leukres.2025.107716_bib10","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2020002538","article-title":"Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?","volume":"4","author":"Rea","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.leukres.2025.107716_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.107716_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"12","key":"10.1016\/j.leukres.2025.107716_bib13","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2025.107716_bib14","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.leukres.2025.107716_bib15","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"French chronic myeloid leukemia study group. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2025.107716_bib16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-free remission with first- and second-generation tyrosine kinase inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107716_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.leukres.2025.107716_bib18","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.3324\/haematol.2022.280811","article-title":"Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial","volume":"107","author":"Dulucq","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.leukres.2025.107716_bib19","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","article-title":"Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission","volume":"4","author":"Rousselot","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2025.107716_bib20","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.066","article-title":"Treatment-free remission in chronic myeloid leukemia harboring atypical BCR-ABL1 transcripts","volume":"12","author":"Dragani","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.leukres.2025.107716_bib21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V91.2.406","article-title":"The SH3 domain contributes to BCR\/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing","volume":"91","author":"Skorski","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107716_bib22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","article-title":"Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis","volume":"189","author":"Nieborowska-Skorska","year":"1999","journal-title":"J. Exp. Med."},{"issue":"21","key":"10.1016\/j.leukres.2025.107716_bib23","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1182\/blood.2023023120","article-title":"Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain","volume":"143","author":"van Outersterp","year":"2024","journal-title":"Blood"},{"issue":"56","key":"10.1016\/j.leukres.2025.107716_bib24","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206094","article-title":"BCR\/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations","volume":"21","author":"Pane","year":"2002","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.leukres.2025.107716_bib25","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2025.107716_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/genes15020232","article-title":"Frequencies of BCR::ABL1 transcripts in patients with chronic myeloid leukemia: a meta-analysis","volume":"15","author":"Romero-Morelos","year":"2024","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.leukres.2025.107716_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.62","article-title":"Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia","volume":"7","author":"Gong","year":"2017","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.leukres.2025.107716_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-022-00696-4","article-title":"Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases","volume":"12","author":"Abdelmagid","year":"2022","journal-title":"Blood Cancer J."},{"issue":"16","key":"10.1016\/j.leukres.2025.107716_bib29","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107716_bib30","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3390\/jcm9051457","article-title":"Novel multiplex droplet digital pcr assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts","volume":"9","author":"Petiti","year":"2020","journal-title":"J. Clin. Med."},{"issue":"22","key":"10.1016\/j.leukres.2025.107716_bib31","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.leukres.2025.107716_bib32","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/ajh.27359","article-title":"BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: an individual participant data meta-analysis","volume":"99","author":"Kockerols","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2025.107716_bib33","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41375-024-02327-2","article-title":"Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation","volume":"38","author":"Ernst","year":"2024","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:59:10Z","timestamp":1749488350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"alternative-id":["S0145212625000761"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107716","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107716"}}